This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Illumina Is How You Play Biotech Without Being in Biotech

Stocks in this article: ILMN

NEW YORK (TheStreet) -- Biotech stocks are volatile and investors have a tendency to trade the whole group together. However, there are opportunities to be found. One is Illumina (ILMN), which is not a biotech but works with the biotech industry.

Illumina was founded in 1998 in San Diego and develops, manufactures and markets integrated systems for the analysis of genetic variation and biological function. Illumina has grown tremendously over the last few years and now employs 3,100+ people worldwide. Last year the company generated $1.42 billion in revenue.

One of the things I like about the Illumina story is it is not dependent on a particular drug or customer.

Looking at Ilumina's stock chart, you can see that after a selloff from March to April, Illumina has come roaring back and is now up 50% for the year. The stock has been trading well since the end of April when it reported a solid quarter, beating earnings estimates by $0.02 and exceeding revenue estimates with management guiding up both earnings and revenue estimates. First-quarter revenue increased an impressive 27% on a year-over-year basis.

ILMN Chart
data by YCharts

Illumina's products are selling well in the marketplace and its HiSeq X Ten low-cost ($1,000), ultra-high-throughput sequencer product is gaining traction even faster than anticipated. The product just starting shipping in Q1 of this year and already received orders for 104 units during the quarter. Illumina's large portfolio of sequencers and market penetration has created a barrier to entry for new competitors.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs